The Drugs Technical Advisory Board (DTAB) has taken key decisions regarding the implementation of the revised Schedule M during its 93rd meeting. This balanced move aims to strengthen drug quality while supporting industry practicality, impacting manufacturing practices across India’s pharmaceutical sector in the coming months.
Job Overview
DTAB has approved amendments to the revised Schedule M. These changes involve stricter microbial contamination limits for “Grade A” manufacturing areas to align with global World Health Organization (WHO) Technical Report Series (TRS) 1044, Annexure II standards. Additionally, DTAB recommended continuing exemptions for select drug categories like medical gases, empty gelatin capsules, and disinfectant fluids, acknowledging that some provisions of the revised Schedule M may not be relevant for these specific categories. This pragmatic approach aims to enhance quality assurance while reducing unnecessary compliance burdens.
Important Dates
The Board deliberated on stakeholder requests regarding exemptions that existed prior to the amendment notified under G.S.R. 922(E) dated December 28, 2023.
Eligibility Criteria
The decisions impact manufacturing practices, specifically affecting microbial limits for “Grade A” areas and providing relief for certain product categories.
Official Notification & Links
Important Instructions
While stricter microbial limits will improve product safety, targeted exemptions will help avoid over-regulation in low-risk segments. This decision reflects DTAB’s intent to strike a balance between adopting stringent global quality standards and addressing practical challenges faced by the pharmaceutical industry.
Conclusion
The revised Schedule M updates represent DTAB’s effort to enhance the quality and sterility assurance of pharmaceutical products, aligning Indian standards with international benchmarks while addressing specific industry concerns.
